Advances in Diabetes Treatment — Once-Weekly Insulin

This editorial discusses the challenges in diabetes management, including inadequate glycemic control despite advancements in therapies. It highlights a study comparing once weekly insulin icodec with daily insulin glargine in patients with type 2 diabetes. The trial demonstrated that icodec was as effective as glargine in reducing glycated hemoglobin levels (from 8.1% to 6.7%) with a lower overall insulin dose, though it had a slightly higher incidence of mild hypoglycemia. The authors note the potential benefits of simplified weekly dosing but caution about the need for further studies to determine optimal patient populations, particularly for those with type 1 diabetes or active lifestyles requiring flexible dosing.

This editorial discusses the challenges in diabetes management, including inadequate glycemic control despite advancements in therapies. It highlights a study comparing once weekly insulin icodec with daily insulin glargine in patients with type 2 diabetes. The trial demonstrated that icodec was as effective as glargine in reducing glycated hemoglobin levels (from 8.1% to 6.7%) with a lower overall insulin dose, though it had a slightly higher incidence of mild hypoglycemia. The authors note the potential benefits of simplified weekly dosing but caution about the need for further studies to determine optimal patient populations, particularly for those with type 1 diabetes or active lifestyles requiring flexible dosing.